Triglyceride-rich lipoprotein regulates APOB48 receptor gene expression in human THP-1 monocytes and macrophages

Journal of Nutrition

Volumn 142, Issue 2, 2012, Pages 227-232

  Bermudez, Beatriz ^a   Lopez, Sergio ^a   Varela, Lourdes M ^a   Ortega, Almudena ^a   Pacheco, Yolanda M ^a   Moreda, Wenceslao ^a   Moreno Luna, Rafael ^b   Abia, Rocio ^a   Muriana, Francisco J G ^a  

^a INSTITUTO DE LA GRASA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B48 RECEPTOR; CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; SMALL INTERFERING RNA; TRIACYLGLYCEROL; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID STORAGE; LIPID TRANSPORT; MACROPHAGE; MONOCYTE; NORMAL HUMAN; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION;

CELL LINE; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HUMANS; LIPOPROTEINS; MACROPHAGES; MONOCYTES; POSTPRANDIAL PERIOD; PPAR ALPHA; PPAR GAMMA; RECEPTORS, LIPOPROTEIN; RETINOID X RECEPTOR ALPHA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRIGLYCERIDES;

EID: 84858195094     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.149963     Document Type: Article

References (27)

1. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem. 1995;41:153-8.
2. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischaemic heart disease, and death in men and women. JAMA. 2007;298:299-308.
3. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B (48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002;13:461-70.
4. Brown ML, Ramprasad MP, Umeda PK, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo WL, Li R, Song R, et al. A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc Natl Acad Sci USA. 2000;97:7488-93.
5. Brown ML, Yui K, Smith JD, LeBoeuf RC, Weng W, Umeda PK, Li R, Song R, Gianturco SH, Bradley WA. The murine macrophage apoB-48 receptor gene (Apob-48r): homology to the human receptor. J Lipid Res. 2002;43:1181-91.
6. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferatoractivated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-78.
7. Haraguchi G, Kobayashi Y, Brown ML, Tanaka A, Isobe M, Gianturco SH, Bradley WA. PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor. J Lipid Res. 2003;44:1224-31.
8. Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, Tanaka A, Shimokado K, Yoshida M. Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol. 2005; 25:424-9.
9. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15: 534-42.
10. Pacheco YM, Abia R, Olivera A, Spiegel S, Ruiz-Gutierrez V, Muriana FJ. Sphingosine 1-phosphate signal survival and mitogenesis are mediated by lipid-stereospecific binding of triacylglycerol-rich lipoproteins. Cell Mol Life Sci. 2003;60:2757-66.
11. Pacheco YM, Bermudez B, Lopez S, Abia R, Villar J, Muriana FJ. Ratio of oleic to palmitic acid is a dietary determinant of thrombogenic and fibrinolytic factors during the postprandial state in men. Am J Clin Nutr. 2006;84:342-9.
12. Alaupovic P, Lee DM, McConathy WJ. Studies on the composition and structure of plasma lipoproteins. Distribution of lipoprotein families in major density classes of normal human plasma lipoproteins. Biochim Biophys Acta. 1972;260:689-707.
13. Mottillo EP, Shen XJ, Granneman JG. β3-adrenergic receptor induction of adipocyte inflammation requires lipolytic activation of stress kinases p38 and JNK. Biochim Biophys Acta. 2010;1801:1048-55.
14. Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM, Vanden Heuvel JP. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J. 2001;356:899-906.
15. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA. 2005;102: 16747-52.
16. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771-4.
17. Hihi AK, Michalik L, Wahli W. PPAR: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci. 2002;59:790-8.
18. Wolfrum C, Borrmann CM, Börchers T, Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA. 2001;98:2323-8.
19. Nicholson AC. Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc Med. 2004;14:8-12.
20. Kong WJ, Liu J, Jiang JD. Human low-density lipoprotein receptor gene and its regulation. J Mol Med. 2006;84:29-36.
21. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci USA. 1998;95:4333-7.
22. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE. Triglyceride accumulation protects against fatty acidinduced lipotoxicity. Proc Natl Acad Sci USA. 2003;100:3077-82.
23. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res. 2005;51:85-94.
24. Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta. 2007;1771:926-35.
25. Ziouzenkova O, Perrey S, Asatryan L, Hwang J, MacNaul KL, Moller DE, Rader DJ, Sevanian A, Zechner R, Hoefler G, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA. 2003;100:2730-5.
26. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009;138:476-88.
27. Chakravarthy MV, Zhu Y, Lopez M, Yin L, Wozniak DF, Coleman T, Hu Z, Wolfgang M, Vidal-Puig A, Lane MD, et al. Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. J Clin Invest. 2007;117:2539-52.